JNCCN 360 - Immunotherapy

Advertisement

Advertisement

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Ian W. Flinn, MD, PhD, on Chronic Lymphocytic Leukemia: Early-Phase Research on Immunotherapy

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Recent

Treatment Duration for Nivolumab in Advanced NSCLC: CheckMate 153

Case Study: Chemoimmunotherapy Combination in Merkel Cell Carcinoma

Adding Zanubrutinib to Obinutuzumab in CLL

Adding Daratumumab to Carfilzomib-Based Therapy in Resistant Myeloma: CANDOR Trial

Published

Medical Literature

Therapeutic Update in AML: Genomic Assessment Is Key

COVID-19 and Multiple Myeloma: Update From Stockholm

Study Explores Potential Prognostic Indicators for Papillary Thyroid Carcinoma

Triple-Negative Breast Cancer: Mixed 19-Peptide Vaccine Monotherapy

Ongoing

Modest Responses With Immunotherapy Combo for Advanced Ovarian Cancer

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

BCOP Test-Advances in Targeted Therapy and Immunotherapy For The Treatment of Kidney Cancer

NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer

Available

Clinical Trials

ClinicalTrials.gov Immunotherapy

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.